ArticleNeurosurgery practice2023

Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol.

Andres Ramos-Fresnedo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.